Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Increased Risk Of Emphysema Following Childhood Exposure To Tobacco Smoke
Chronic exposure to tobacco smoke in childhood may contribute to early emphysema later in life, according to new research. Environmental tobacco smoke (ETS) is known to be associated with a variety of serious health problems, but it had not previously been associated with the development of emphysema over the life course. The data was presented on Tuesday, May 19, at the 105th International Conference of the American Thoracic Society in San Diego.
generic viagra online
New Malaria Vaccine Approach To Be Tested By PATH Malaria Vaccine Initiative And Crucell
The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Dutch biopharmaceutical company Crucell N.V. today announced a collaboration to accelerate development of a promising type of malaria vaccine. Through funding from the USAID MVDP, the partners will conduct studies to determine the effectiveness of Crucell"s novel prime-boost vaccine approach against the malaria parasite, Plasmodium falciparum. This approach uses Crucell"s proprietary recombinant adenoviruses (a type of virus associated with the common cold and other mild respiratory infections) to deliver a malaria antigen to the immune system.
News of the day
Motor Molecules Use Random Walks To Make Deliveries In Living Cells
Cells rely on tiny molecular motors to deliver cargo, such as mRNA and organelles, within the cell. The critical nature of this transport system is evidenced by the fact that disruption of motors by genetic defects leads to fatal diseases in humans. Although investigators have isolated these motor to study their function in a controlled environment outside the cell, it has been difficult for researchers to follow these fascinating molecular transporters in their natural environment, the living cell.
Medical Devices

Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients With Complicated Urinary Tract Infections

Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients. The multi-center, randomized study is anticipated to enroll approximately 120 patients and will compare the efficacy and safety of CXA-101 with the current standard of therapy. The primary efficacy endpoint for this study is microbiological outcome at the test-of-cure visit between six to nine days after the end of therapy. "The preclinical and Phase 1 results to date are very promising and indicate that CXA-101 is well tolerated and has broad-spectrum antibacterial coverage, including potent activity against increasingly resistant gram-negative pathogens such as Pseudomonas aeruginosa," said Dr. Ian Friedland, chief medical officer of Calixa. "We are going to present comprehensive preclinical and Phase 1 data at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy in September and other medical conferences. This Phase 2 study will generate important information on the safety and effectiveness of CXA-101 in complicated urinary tract infections, which are usually caused by gram-negative pathogens". Eckard Weber, president and chief executive officer of Calixa and partner at the venture capital firm Domain Associates, LLC said, "With the continually increasing incidence of serious and life-threatening infections caused by resistant gram-negative bacteria and the paucity of new drugs in the pipeline to counter such resistance, we are working diligently to expedite the development of CXA-101. We are fully committed to providing patients and physicians with a much needed option for the treatment of life-threatening infections caused by gram-negative bacteria." About Calixa Therapeutics Calixa Therapeutics Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of infectious diseases. The company"s initial focus is on developing novel antibiotics for use in the hospital setting. Calixa Therapeutics, which is privately held, is headquartered in San Diego and has operations in the San Francisco Bay Area. Calixa Therapeutics Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009